Literature DB >> 8175724

Noncovalent complexes between the lysosomal proteinase cathepsin B and its propeptide account for stable, extracellular, high molecular mass forms of the enzyme.

L Mach1, J S Mort, J Glössl.   

Abstract

Although the lysosomal cysteine proteinase cathepsin B is alkaline pH-labile, active, stable high molecular mass forms have been reported previously from the culture medium of human and murine mammary tumor explants and the sputum of patients with purulent bronchiectasis. A similar, catalytically active, high molecular mass form of recombinant human cathepsin B produced in yeast has now been found to represent a noncovalent complex between the 30-kDa single chain enzyme and its 6-kDa propeptide formed during autocatalytic maturation of the proenzyme (see accompanying article; Mach, L., Mort, J. S., and Glössl, J. (1994) J. Biol. Chem. 269, 13030-13035). Incubation of the complex under acidic conditions resulted in dissociation and degradation of the inhibitory propeptide leading to increased enzymatic activity, as also observed for partially purified cathepsin B isoenzymes from purulent sputum and mammary tumor explant media. The stabilization of the processed proteinase as a noncovalent complex with its proregion provides an important mechanism whereby extracellular cathepsin B can lie dormant until regional acidification mediates its activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175724

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Plant proteolytic enzymes: possible roles during programmed cell death.

Authors:  E P Beers; B J Woffenden; C Zhao
Journal:  Plant Mol Biol       Date:  2000-10       Impact factor: 4.076

Review 2.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

3.  Rubella virus nonstructural protein protease domains involved in trans- and cis-cleavage activities.

Authors:  Y Liang; J Yao; S Gillam
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Expression and characterization of a recombinant cysteine proteinase of Leishmania mexicana.

Authors:  S J Sanderson; K G Pollock; J D Hilley; M Meldal; P S Hilaire; M A Juliano; L Juliano; J C Mottram; G H Coombs
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

5.  The Arabidopsis xylem peptidase XCP1 is a tracheary element vacuolar protein that may be a papain ortholog.

Authors:  Vanessa Funk; Boonthida Kositsup; Chengsong Zhao; Eric P Beers
Journal:  Plant Physiol       Date:  2002-01       Impact factor: 8.340

6.  Proteinases and their inhibitors in liver cancer.

Authors:  Verena Puxbaum; Lukas Mach
Journal:  World J Hepatol       Date:  2009-10-31

7.  'Patchiness' and basic cancer research: unravelling the proteases.

Authors:  Surinder M Soond; Maria V Kozhevnikova; Andrey A Zamyatnin
Journal:  Cell Cycle       Date:  2019-06-24       Impact factor: 4.534

8.  Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples.

Authors:  M R Emmert-Buck; M J Roth; Z Zhuang; E Campo; J Rozhin; B F Sloane; L A Liotta; W G Stetler-Stevenson
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

9.  M6P/IGF2R modulates the invasiveness of liver cells via its capacity to bind mannose 6-phosphate residues.

Authors:  Verena Puxbaum; Elisabeth Nimmerfall; Christine Bäuerl; Nicole Taub; Pia-Maria Blaas; Johannes Wieser; Mario Mikula; Wolfgang Mikulits; Ken M Ng; George C T Yeoh; Lukas Mach
Journal:  J Hepatol       Date:  2012-04-17       Impact factor: 25.083

10.  Human cysteine cathepsins are not reliable markers of infection by Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Clément Naudin; Alix Joulin-Giet; Gérard Couetdic; Patrick Plésiat; Aneta Szymanska; Emilia Gorna; Francis Gauthier; Franciszek Kasprzykowski; Fabien Lecaille; Gilles Lalmanach
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.